This robotic surgical systems pioneer is dealing with a few issues, but its opportunities remain promising.

Investing.com -- TD Cowen initiated coverage of Intuitive Surgical with a Buy rating and a $660 price target, saying the launch of the da Vinci 5 system is driving a long-tailed product cycle that can ...

The surgical robotics maker posts better-than-expected quarterly earnings as it begins rollout of cardiac procedures.

Soft tissue robotic systems designed to improve surgical precision are expanding into new specialties and increasing ...

Intuitive Surgical, Inc. has reported past fourth-quarter 2025 revenue of US$2.87 billion and full-year revenue of US$10.06 ...

The FDA 510(k) clearances for cardiac procedures cover Intuitive's latest-generation da Vinci 5 (DV5) using non-Force ...

Intuitive Surgical capped off the recovery in its shares with a strong Q4 2025 earnings release, lending support to the stock ...

Intuitive Surgical reported revenue of $2.87 billion for the fourth quarter, beating analyst estimates of $2.75 billion, ...

MemorialCare Long Beach Medical Center is a regional leader in robotic surgery with the new da Vinci 5. See how this tech ...

The robotics giant revealed on an earnings call that it won FDA clearance for several cardiac procedures and is also ramping up its presence in ambulatory surgery centers.

Intuitive Surgical (NASDAQ: ISRG) reports in-line Q4 results, sets measured guidance for 2026, with an 18% revenue growth and ...

Oath Surgical founder and CEO Oliver Keown, a former surgeon, was a founder of Intuitive Ventures, the venture unit or ...